ProKidney Corp. (PROK)

2.2000 +0.0500 (+2.33%) 收市：04:00PM EDT

ProKidney Corp.

2000 Frontis Plaza Blvd.
Suite 250
Winston-Salem, NC 27103
United States
336 999 7028
https://www.prokidney.com

版塊: Healthcare
行業: Biotechnology
全職員工: 163

描述

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

公司管治

截至 2024年5月1日 止，ProKidney Corp. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：10；董事會：7；股東權利：4；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。